Dora I A Pereira

Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2018-2021
Publications (10 Years): 3

Top Topics

Squamous Cell Carcinoma

Antimicrobial Resistance

Placebo Controlled

Top Venues

Gates open research

British journal of clinical pharmacology

Vifor Pharma UK Ltd

University of Reading (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Vifor Pharma UK Ltd Dec 01 2018

United Kingdom

Medical Advisor :: Medical Affairs

University of Cambridge Apr 01 2016 - Nov 30 2018

United Kingdom

Group Leader :: Pathology

Medical Research Council Jul 03 2014 - Mar 31 2016

United Kingdom

Senior Investigator Scientist :: Human Nutrition Research

Medical Research Council Jun 01 2005 - Jul 02 2014

United Kingdom

Investigator Scientist :: Human Nutrition Research

Medical Research Council Feb 01 2003 - May 31 2005

United Kingdom

Visiting post-doctoral fellow :: Human Nutrition Research

Education History

University of Reading Oct 01 1999 - Aug 15 2003

United Kingdom

PHD :: Food Biosciences

Publications

Giovanna Culeddu, Li Su, Yafeng Cheng, Dora I A Pereira, Rupert A Payne, Jonathan J Powell, Dyfrig A Hughes
Novel oral iron therapy for iron deficiency anaemia: How to value safety in a new drug? British journal of clinical pharmacology (2021)
Dora I A Pereira, Nuredin I Mohammed, Ogochukwu Ofordile, Famalang Camara, Bakary Baldeh, Thomas Mendy, Chilel Sanyang, Amadou T Jallow, Ilias Hossain, James Wason, Andrew M Prentice
A novel nano-iron supplement to safely combat iron deficiency and anaemia in young children: The IHAT-GUT double-blind, randomised, placebo-controlled trial protocol. Gates open research (2018)
Dora I A Pereira, Nuredin I Mohammed, Ogochukwu Ofordile, Famalang Camara, Bakary Baldeh, Thomas Mendy, Chilel Sanyang, Amadou T Jallow, Ilias Hossain, James Wason, Andrew M Prentice
A novel nano-iron supplement to safely combat iron deficiency and anaemia in young children: The IHAT-GUT double-blind, randomised, placebo-controlled trial protocol. Gates open research 2 (2018)